In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes

Autores
Aparicio, Evangelina; Luthy, Isabel Alicia
Año de publicación
2021
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.
Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Buenos Aires Breast Cancer Symposium
Buenos Aires
Argentina
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Consejo Nacional de Investigaciones Científicas y Técnicas
Instituto de Biología y Medicina Experimental
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Investigaciones en Medicina Traslacional
Instituto de Nanosistemas
Universidad Austral
Universidad de Buenos Aires
Universidad Nacional de San Martín
Materia
MICRORNA
ADRENERGIC RECEPTORS
BREAST CANCER
BIOINFORMATICS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/152262
Acceder
id CONICETDig_323fbb36730e3fb8ec0050d997b52ad5
oai_identifier_str oai:ri.conicet.gov.ar:11336/152262
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypesAparicio, EvangelinaLuthy, Isabel AliciaMICRORNAADRENERGIC RECEPTORSBREAST CANCERBIOINFORMATICShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBuenos Aires Breast Cancer SymposiumBuenos AiresArgentinaCentro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”Consejo Nacional de Investigaciones Científicas y TécnicasInstituto de Biología y Medicina ExperimentalInstituto de Fisiología, Biología Molecular y NeurocienciasInstituto de Investigaciones en Medicina TraslacionalInstituto de NanosistemasUniversidad AustralUniversidad de Buenos AiresUniversidad Nacional de San MartínFundación Revista MedicinaKordon, Edith ClaudiaLanari, Claudia Lee MalvinaSimian, Marina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectSimposioJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/152262In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-280025-76801669-9106CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.cominfo:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:13:51Zoai:ri.conicet.gov.ar:11336/152262instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:13:51.606CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
title In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
spellingShingle In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
Aparicio, Evangelina
MICRORNA
ADRENERGIC RECEPTORS
BREAST CANCER
BIOINFORMATICS
title_short In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
title_full In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
title_fullStr In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
title_full_unstemmed In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
title_sort In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes
dc.creator.none.fl_str_mv Aparicio, Evangelina
Luthy, Isabel Alicia
author Aparicio, Evangelina
author_facet Aparicio, Evangelina
Luthy, Isabel Alicia
author_role author
author2 Luthy, Isabel Alicia
author2_role author
dc.contributor.none.fl_str_mv Kordon, Edith Claudia
Lanari, Claudia Lee Malvina
Simian, Marina
dc.subject.none.fl_str_mv MICRORNA
ADRENERGIC RECEPTORS
BREAST CANCER
BIOINFORMATICS
topic MICRORNA
ADRENERGIC RECEPTORS
BREAST CANCER
BIOINFORMATICS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.
Fil: Aparicio, Evangelina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Luthy, Isabel Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Buenos Aires Breast Cancer Symposium
Buenos Aires
Argentina
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Consejo Nacional de Investigaciones Científicas y Técnicas
Instituto de Biología y Medicina Experimental
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Investigaciones en Medicina Traslacional
Instituto de Nanosistemas
Universidad Austral
Universidad de Buenos Aires
Universidad Nacional de San Martín
description Breast cancer (BC) is the most frequently diagnosed and leading cause of cancer death among women worldwide. We previously described that the expression of the α2A adrenoceptor (ADRA2A) is an independent good prognostic factor in luminal tumors. We interrogated in the public TCGA database the expression of miRNAs able to bind to the ADRA2A 3´UTR and we selected for further studies those which correlated with ADRA2A expression. The cutoff points for disease-free survival (DFS) were selected using the Evaluate Cutpoint. Survival analysis was performed by Kaplan?Meier and log‐rank (Mantel?Cox).A high expression of ADRA2A was significantly associated with better DFS as previously shown. hsa-miR 23a-3p, 30a-5p, 30e-5p, 33a-5p, 33b-5p, 135b-5p and 138-5p correlated with ADRA2A expression. When they were evaluated for prognosis ability, a high expression of 135b-5p proved significantly associated with DFS in the whole cohort and in basal-like tumors in particular. The opposite was found for 23a-3p. A high expression of 30e-5p was associated with better DFS in luminal A, while 33a-5p was associated with longer DFS in luminal tumors in general, and luminal B in particular. In fact, high 30e-5p and 33a-5p expression exhibited 100% DFS in these subtypes. 30e-5p was overexpressed in luminal A (as has already been described) and 23a-3p, 30e-5p, 33a-5p, 135b-5p and 138-5p in basal-like tumors. These miRNAs and ADRA2A might be selectively used as prognostic biomarkers in the different BC subtypes.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Simposio
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/152262
In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-28
0025-7680
1669-9106
CONICET Digital
CONICET
url http://hdl.handle.net/11336/152262
identifier_str_mv In silico identification of ADRA2A-associated miRNA expression as biomarkers for disease-free survival in breast cancer subtypes; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 28-28
0025-7680
1669-9106
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.medicinabuenosaires.com
info:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781551779512320
score 12.982451

Publicaciones similares